Safety evaluation of irinotecan: a real-world disproportionality analysis using FAERS and JADER databases during the time period 2004-2024
This comparative analysis revealed multiple consistent and unexpected signals related to irinotecan use. The findings emphasize the importance of region-specific pharmacovigilance and the need for heightened awareness of both labeled and unlabeled toxicities. Our results support continued monitoring and further investigation into temporal patterns and regional differences in irinotecan-related adverse events to enhance clinical safety.
Authors
- Zhiwei Cui (ORCID: https://orcid.org/0000-0001-8338-4270)
- Huayou Chen (ORCID: https://orcid.org/0000-0002-7312-0367)
- Fan Zou (ORCID: https://orcid.org/0000-0002-4436-6923)
- Xiyuan Zhang (ORCID: https://orcid.org/0000-0002-4644-3953)
- Liyuan Zhou (ORCID: https://orcid.org/0000-0001-7485-8163)
- Siyu Lou
- Yingyong Ou
- Chengyu Zhu (ORCID: https://orcid.org/0000-0002-2885-7394)
Institutions
- Zunyi Medical University (CN)
- Yanan University Affiliated Hospital (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Hainan Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-06-09
- DOI
- https://doi.org/10.3389/fphar.2025.1516449
- Citations
- 5
- Primary Topic
- Cancer therapeutics and mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 4.03
Funders
- Health Commission of Guizhou Province